GLOBAL OPHTHALMIC DRUGS MARKET FORECAST 2017-2025
KEY FINDINGS
The global ophthalmic drugs market is estimated to grow at an approximate CAGR of 4.15% during the period of 2017 and 2024. An existing predominance and increase in the number of eye disorders with growing geriatric population all over the world are the primary drivers responsible for the market growth. With increasing awareness of ophthalmic drugs among the consumers and patients is anticipated to proliferate the market growth.
MARKET INSIGHTS
The ophthalmic drugs market is segmented on the basis of End-user, Prescription type, and Geography. The Prescription type ophthalmic drugs market is segregated into Prescription Market for Ophthalmic Drugs and OTC (Over the Counter Drugs) Market for Ophthalmic Drugs. The End-user ophthalmic drugs market is segregated into Hospitals, Eye Clinics, Diagnostic Centers, and Patients. The ophthalmic drugs market on the basis of Geography is segregated into Asia-Pacific, Europe, North America, Middle East & Africa and Central & South America.
The technological advancements, rise in eye disorders, growth in geriatric population, cataract surgeries and upsurge in healthcare expenditure are dominant drivers for the growth of ophthalmic drugs market. A vast scope for ophthalmic drugs market is created with the predominance of eye-related disorders and ailments. One major cause for half-blindness and decreased vision is Cataract with the highest percentage accountable of worldwide visual impairment. Cataract surgery is risk-free and secure kind of surgery; the safety has led to an increase in the cataract surgeries. The boost in Health expenditure has boosted the consumer spending indirectly driving the ophthalmic drugs market.
REGIONAL INSIGHTS
North America accounts for the largest market share in the global ophthalmic drugs market. Europe accounts for a second largest market share in the global ophthalmic drugs market. Asia-Pacific is estimated to expand at the highest CAGR during the forecast period. Asia-Pacific is also anticipated to emerge as a leading destination for drug development during the forecast years. The rise in aged population and existence of dominant market players in the regions are driving the regional markets. The Middle East & Africa and Central & South America ophthalmic drugs market are projected to expand during the forecast years with the rise in aged population and predominance of eye ailments amongst the population.
COMPETITIVE INSIGHTS
The predominant ophthalmic drugs companies in the global market are Bayer, Akorn, Johnson and Johnson, Abbott Laboratories, Valeant, Allergan Inc., Regeneron, Merck & Co., Pfizer Inc., Lpath Incorporated, Novartis Ag, Roche Holding Ag, Eyegate Pharmaceuticals, GlaxoSmithKline, Santen Pharmaceutical Co. Ltd, Sun Pharmaceuticals Industries, Ltd., Senju Pharmaceutical Co., Ltd, Cipla Pharmaceuticals and EyeMed.
The global ophthalmic drugs market is estimated to grow at an approximate CAGR of 4.15% during the period of 2017 and 2024. An existing predominance and increase in the number of eye disorders with growing geriatric population all over the world are the primary drivers responsible for the market growth. With increasing awareness of ophthalmic drugs among the consumers and patients is anticipated to proliferate the market growth.
MARKET INSIGHTS
The ophthalmic drugs market is segmented on the basis of End-user, Prescription type, and Geography. The Prescription type ophthalmic drugs market is segregated into Prescription Market for Ophthalmic Drugs and OTC (Over the Counter Drugs) Market for Ophthalmic Drugs. The End-user ophthalmic drugs market is segregated into Hospitals, Eye Clinics, Diagnostic Centers, and Patients. The ophthalmic drugs market on the basis of Geography is segregated into Asia-Pacific, Europe, North America, Middle East & Africa and Central & South America.
The technological advancements, rise in eye disorders, growth in geriatric population, cataract surgeries and upsurge in healthcare expenditure are dominant drivers for the growth of ophthalmic drugs market. A vast scope for ophthalmic drugs market is created with the predominance of eye-related disorders and ailments. One major cause for half-blindness and decreased vision is Cataract with the highest percentage accountable of worldwide visual impairment. Cataract surgery is risk-free and secure kind of surgery; the safety has led to an increase in the cataract surgeries. The boost in Health expenditure has boosted the consumer spending indirectly driving the ophthalmic drugs market.
REGIONAL INSIGHTS
North America accounts for the largest market share in the global ophthalmic drugs market. Europe accounts for a second largest market share in the global ophthalmic drugs market. Asia-Pacific is estimated to expand at the highest CAGR during the forecast period. Asia-Pacific is also anticipated to emerge as a leading destination for drug development during the forecast years. The rise in aged population and existence of dominant market players in the regions are driving the regional markets. The Middle East & Africa and Central & South America ophthalmic drugs market are projected to expand during the forecast years with the rise in aged population and predominance of eye ailments amongst the population.
COMPETITIVE INSIGHTS
The predominant ophthalmic drugs companies in the global market are Bayer, Akorn, Johnson and Johnson, Abbott Laboratories, Valeant, Allergan Inc., Regeneron, Merck & Co., Pfizer Inc., Lpath Incorporated, Novartis Ag, Roche Holding Ag, Eyegate Pharmaceuticals, GlaxoSmithKline, Santen Pharmaceutical Co. Ltd, Sun Pharmaceuticals Industries, Ltd., Senju Pharmaceutical Co., Ltd, Cipla Pharmaceuticals and EyeMed.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. OTC PRESCRIPTION MARKET HOLDS THE LARGEST MARKET SHARE
3.2.2. EYE CANCER THERAPEUTICS MARKET IS GROWING SIGNIFICANTLY
3.2.3. EYE CLINICS HOLDS THE LARGEST MARKET SHARE IN TERMS OF END USER SEGMENT
3.2.4. ASIA PACIFIC REGION IS GROWING AT A FASTER RATE
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. INCREASING GERIATRIC POPULATION GLOBALLY
4.1.2. TECHNOLOGICAL ADVANCEMENT
4.1.3. RISING PREVALENCE OF EYE DISORDERS
4.1.4. INCREASED HEALTHCARE EXPENDITURE
4.1.5. CATARACT SURGERIES ON RISE
4.2. MARKET RESTRAINTS
4.2.1. RENOWNED DRUGS GOING OFF-PATENT
4.2.2. DELAY IN DRUG APPROVALS
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASE IN DISORDER SYMPTOM AWARENESS LEADING TO HIGHER TREATMENT RATES
4.3.2. GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
5. MARKET SEGMENTATION
5.1. MARKET BY PRESCRIPTION TYPE 2017-2025
5.1.1. PRESCRIPTION OPHTHALMIC DRUGS
5.1.2. OTC
5.2. MARKET BY END USER 2017-2025
5.2.1. EYE CLINICS OPHTHALMIC DRUGS
5.2.2. HOSPITAL OPHTHALMIC DRUGS
5.2.3. DIAGNOSTIC CENTERS OPHTHALMIC DRUGS
5.2.4. PATIENTS OPHTHALMIC DRUGS
5.3. MARKET BY THERAPEUTICS 2017-2025
5.3.1. DIABETIC MACULAR EDEMA
5.3.2. EYE CANCER
5.3.3. DIABETIC RETINOPATHY
5.3.4. RETINAL VEIN OCCLUSION
5.3.5. AGE-RELATED MACULAR DEGENERATION
5.3.6. CONJUNCTIVITIS
5.3.7. DRY EYE
5.3.8. GLAUCOMA
5.3.9. KERATITIS
5.3.10. LENS OPACIFICATION AND INTRAOCULAR LENS
5.3.11. GEOGRAPHIC ATROPHY
5.3.12. LENS OPACIFICATION AND INTRAOCULAR LENS
6. KEY ANALYTICS
6.1. VALUE CHAIN ANALYSIS
6.1.1. RESEARCH AND DEVELOPMENT
6.1.2. MANUFACTURING
6.1.3. MARKETING AND DISTRIBUTION
6.2. PORTER’S FIVE FORCES ANALYSIS
6.2.1. BARGAINING POWER BUYERS
6.2.2. BARGAINING POWER OF SUPPLIER
6.2.3. THREATS OF NEW ENTRANTS
6.2.4. THREATS OF SUBSTITUTES
6.2.5. COMPETITIVE RIVALRY
6.3. SEE-SAW ANALYSIS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
7.1.3. MEXICO
7.2. EUROPE
7.2.1. GERMANY
7.2.2. UNITED KINGDOM
7.2.3. RUSSIA
7.2.4. FRANCE
7.2.5. ITALY
7.2.6. SPAIN
7.3. ASIA PACIFIC
7.3.1. CHINA
7.3.2. INDIA
7.3.3. SOUTH KOREA
7.3.4. JAPAN
7.3.5. AUSTRALIA
7.4. REST OF WORLD
7.4.1. MIDDLE EAST & AFRICA
7.4.2. CENTRAL &SOUTH AMERICA
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.2. ALLERGAN INC.
8.3. JOHNSON AND JOHNSON
8.4. BAYER
8.5. VALEANT
8.6. REGENERON
8.7. AKORN
8.8. EYEMED
8.9. SENJU PHARMACEUTICAL CO., LTD
8.10. PFIZER INC.
8.11. MERCK & CO.
8.12. NOVARTIS AG
8.13. GLAXOSMITHKLINE
8.14. EYEGATE PHARMACEUTICALS
8.15. LPATH INCORPORATED
8.16. ROCHE HOLDING AG
8.17. SANTEN PHARMACEUTICAL CO. LTD
8.18. CIPLA PHARMACEUTICALS
8.19. SUN PHARMACEUTICALS INDUSTRIES, LTD.
TABLE LIST
TABLE 1 GLOBAL OPHTHALMIC DRUG MARKET REVENUE BY GEOGRAPHY 2017-2025($ MILLION)
TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 3 EYE DRUGS GONE OFF-PATENT
TABLE 4 GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 5 FDA APPROVED DRUGS FOR OPHTHALMOLOGY
TABLE 6 DETAILS OF SOME KEY PRESCRIPTION DRUG
TABLE 7 OPHTHALMIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE
TABLE 8 GLOBAL OPHTHALMIC DRUGS MARKET BY END USER 2017 - 2025 ($ MILLION)
TABLE 9 TOTAL OPHTHALMIC CARE HOSPITAL IN UNITED STATES
TABLE 10 GLOBAL OPHTHALMIC DRUGS MARKET BY THERAPEUTICS 2017-2025 ($ MILLION)
TABLE 11 SYMPTOMS, TREATMENT, AND RECOVERY TIME FOR DIABETIC MACULAR EDEMA
TABLE 12 GLOBAL OPHTHALMIC DRUGS MARKET IN DIABETIC MACULAR EDEMA BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 13 SYMPTOMS AND TREATMENT FOR EYE CANCER
TABLE 14 GLOBAL OPHTHALMIC DRUGS MARKET IN EYE CANCER BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 15 GLOBAL OPHTHALMIC DRUGS MARKET IN DIABETIC RETINOPATHY BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 16 GLOBAL OPHTHALMIC DRUGS MARKET IN RETINAL VEIN OCCLUSION BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 17 GLOBAL OPHTHALMIC DRUGS MARKET IN AGE-RELATED MACULAR DEGENERATION BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 18 GLOBAL OPHTHALMIC DRUGS MARKET IN CONJUNCTIVITIS BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 19 GLOBAL OPHTHALMIC DRUGS MARKET IN DRY EYE BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 20 GLOBAL OPHTHALMIC DRUGS MARKET IN GLAUCOMA THERAPEUTICS BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 21 GLOBAL OPHTHALMIC DRUGS MARKET IN KERATITIS BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 22 GLOBAL OPHTHALMIC DRUGS MARKET IN GEOGRAPHIC ATROPHY BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 23 GLOBAL OPHTHALMIC DRUGS MARKET, BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 24 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 25 UNITED STATES OPHTHALMIC DRUGS MARKET BY END USER 2017-2025 ($ MILLION)
TABLE 26 UNITED STATES HOSPITAL FACT SHEET, 2016
TABLE 27 CANADA OPHTHALMIC DRUGS MARKET BY END USER 2017-2025 ($ MILLION)
TABLE 28 MEXICO OPHTHALMIC DRUGS MARKET BY END USER 2017-2025 ($ MILLION)
TABLE 29 EXTRAPOLATION OF PREVALENCE RATE OF GLAUCOMA BY COUNTRIES
TABLE 30 EUROPE OPHTHALMIC DRUGS MARKET BY GEOGRAPHY 2017–2025 ($ MILLION)
TABLE 31 GERMANY OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025($ MILLION)
TABLE 32 UK OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 33 RUSSIA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 34 NUMBER OF HOSPITALS IN RUSSIAN COUNTRIES, 2015
TABLE 35 FRANCE OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 36 ITALY OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 37 SPAIN OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 38 ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 39 PREVALENCE RATE OF EYE RELATED DISEASES IN CHINA, 2014
TABLE 40 CHINA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 41 INDIA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 42 HUMAN RESOURCE NEEDS FOR EYE CARE IN INDIA
TABLE 43 SOUTH KOREA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 44 JAPAN OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 45 AUSTRALIA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 46 MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 47 CENTRAL & SOUTH AMERICA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. OTC PRESCRIPTION MARKET HOLDS THE LARGEST MARKET SHARE
3.2.2. EYE CANCER THERAPEUTICS MARKET IS GROWING SIGNIFICANTLY
3.2.3. EYE CLINICS HOLDS THE LARGEST MARKET SHARE IN TERMS OF END USER SEGMENT
3.2.4. ASIA PACIFIC REGION IS GROWING AT A FASTER RATE
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. INCREASING GERIATRIC POPULATION GLOBALLY
4.1.2. TECHNOLOGICAL ADVANCEMENT
4.1.3. RISING PREVALENCE OF EYE DISORDERS
4.1.4. INCREASED HEALTHCARE EXPENDITURE
4.1.5. CATARACT SURGERIES ON RISE
4.2. MARKET RESTRAINTS
4.2.1. RENOWNED DRUGS GOING OFF-PATENT
4.2.2. DELAY IN DRUG APPROVALS
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASE IN DISORDER SYMPTOM AWARENESS LEADING TO HIGHER TREATMENT RATES
4.3.2. GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
5. MARKET SEGMENTATION
5.1. MARKET BY PRESCRIPTION TYPE 2017-2025
5.1.1. PRESCRIPTION OPHTHALMIC DRUGS
5.1.2. OTC
5.2. MARKET BY END USER 2017-2025
5.2.1. EYE CLINICS OPHTHALMIC DRUGS
5.2.2. HOSPITAL OPHTHALMIC DRUGS
5.2.3. DIAGNOSTIC CENTERS OPHTHALMIC DRUGS
5.2.4. PATIENTS OPHTHALMIC DRUGS
5.3. MARKET BY THERAPEUTICS 2017-2025
5.3.1. DIABETIC MACULAR EDEMA
5.3.2. EYE CANCER
5.3.3. DIABETIC RETINOPATHY
5.3.4. RETINAL VEIN OCCLUSION
5.3.5. AGE-RELATED MACULAR DEGENERATION
5.3.6. CONJUNCTIVITIS
5.3.7. DRY EYE
5.3.8. GLAUCOMA
5.3.9. KERATITIS
5.3.10. LENS OPACIFICATION AND INTRAOCULAR LENS
5.3.11. GEOGRAPHIC ATROPHY
5.3.12. LENS OPACIFICATION AND INTRAOCULAR LENS
6. KEY ANALYTICS
6.1. VALUE CHAIN ANALYSIS
6.1.1. RESEARCH AND DEVELOPMENT
6.1.2. MANUFACTURING
6.1.3. MARKETING AND DISTRIBUTION
6.2. PORTER’S FIVE FORCES ANALYSIS
6.2.1. BARGAINING POWER BUYERS
6.2.2. BARGAINING POWER OF SUPPLIER
6.2.3. THREATS OF NEW ENTRANTS
6.2.4. THREATS OF SUBSTITUTES
6.2.5. COMPETITIVE RIVALRY
6.3. SEE-SAW ANALYSIS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
7.1.3. MEXICO
7.2. EUROPE
7.2.1. GERMANY
7.2.2. UNITED KINGDOM
7.2.3. RUSSIA
7.2.4. FRANCE
7.2.5. ITALY
7.2.6. SPAIN
7.3. ASIA PACIFIC
7.3.1. CHINA
7.3.2. INDIA
7.3.3. SOUTH KOREA
7.3.4. JAPAN
7.3.5. AUSTRALIA
7.4. REST OF WORLD
7.4.1. MIDDLE EAST & AFRICA
7.4.2. CENTRAL &SOUTH AMERICA
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.2. ALLERGAN INC.
8.3. JOHNSON AND JOHNSON
8.4. BAYER
8.5. VALEANT
8.6. REGENERON
8.7. AKORN
8.8. EYEMED
8.9. SENJU PHARMACEUTICAL CO., LTD
8.10. PFIZER INC.
8.11. MERCK & CO.
8.12. NOVARTIS AG
8.13. GLAXOSMITHKLINE
8.14. EYEGATE PHARMACEUTICALS
8.15. LPATH INCORPORATED
8.16. ROCHE HOLDING AG
8.17. SANTEN PHARMACEUTICAL CO. LTD
8.18. CIPLA PHARMACEUTICALS
8.19. SUN PHARMACEUTICALS INDUSTRIES, LTD.
TABLE LIST
TABLE 1 GLOBAL OPHTHALMIC DRUG MARKET REVENUE BY GEOGRAPHY 2017-2025($ MILLION)
TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 3 EYE DRUGS GONE OFF-PATENT
TABLE 4 GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 5 FDA APPROVED DRUGS FOR OPHTHALMOLOGY
TABLE 6 DETAILS OF SOME KEY PRESCRIPTION DRUG
TABLE 7 OPHTHALMIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE
TABLE 8 GLOBAL OPHTHALMIC DRUGS MARKET BY END USER 2017 - 2025 ($ MILLION)
TABLE 9 TOTAL OPHTHALMIC CARE HOSPITAL IN UNITED STATES
TABLE 10 GLOBAL OPHTHALMIC DRUGS MARKET BY THERAPEUTICS 2017-2025 ($ MILLION)
TABLE 11 SYMPTOMS, TREATMENT, AND RECOVERY TIME FOR DIABETIC MACULAR EDEMA
TABLE 12 GLOBAL OPHTHALMIC DRUGS MARKET IN DIABETIC MACULAR EDEMA BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 13 SYMPTOMS AND TREATMENT FOR EYE CANCER
TABLE 14 GLOBAL OPHTHALMIC DRUGS MARKET IN EYE CANCER BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 15 GLOBAL OPHTHALMIC DRUGS MARKET IN DIABETIC RETINOPATHY BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 16 GLOBAL OPHTHALMIC DRUGS MARKET IN RETINAL VEIN OCCLUSION BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 17 GLOBAL OPHTHALMIC DRUGS MARKET IN AGE-RELATED MACULAR DEGENERATION BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 18 GLOBAL OPHTHALMIC DRUGS MARKET IN CONJUNCTIVITIS BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 19 GLOBAL OPHTHALMIC DRUGS MARKET IN DRY EYE BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 20 GLOBAL OPHTHALMIC DRUGS MARKET IN GLAUCOMA THERAPEUTICS BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 21 GLOBAL OPHTHALMIC DRUGS MARKET IN KERATITIS BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 22 GLOBAL OPHTHALMIC DRUGS MARKET IN GEOGRAPHIC ATROPHY BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 23 GLOBAL OPHTHALMIC DRUGS MARKET, BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 24 NORTH AMERICA OPHTHALMIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 25 UNITED STATES OPHTHALMIC DRUGS MARKET BY END USER 2017-2025 ($ MILLION)
TABLE 26 UNITED STATES HOSPITAL FACT SHEET, 2016
TABLE 27 CANADA OPHTHALMIC DRUGS MARKET BY END USER 2017-2025 ($ MILLION)
TABLE 28 MEXICO OPHTHALMIC DRUGS MARKET BY END USER 2017-2025 ($ MILLION)
TABLE 29 EXTRAPOLATION OF PREVALENCE RATE OF GLAUCOMA BY COUNTRIES
TABLE 30 EUROPE OPHTHALMIC DRUGS MARKET BY GEOGRAPHY 2017–2025 ($ MILLION)
TABLE 31 GERMANY OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025($ MILLION)
TABLE 32 UK OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 33 RUSSIA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 34 NUMBER OF HOSPITALS IN RUSSIAN COUNTRIES, 2015
TABLE 35 FRANCE OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 36 ITALY OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 37 SPAIN OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 38 ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 39 PREVALENCE RATE OF EYE RELATED DISEASES IN CHINA, 2014
TABLE 40 CHINA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 41 INDIA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 42 HUMAN RESOURCE NEEDS FOR EYE CARE IN INDIA
TABLE 43 SOUTH KOREA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 44 JAPAN OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 45 AUSTRALIA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 46 MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
TABLE 47 CENTRAL & SOUTH AMERICA OPHTHALMIC DRUGS MARKET BY END-USER 2017-2025 ($ MILLION)
FIGURES LIST
FIGURE 1 THE POPULATION OF PEOPLE AGED 65 AND OVER WILL DOUBLE IN THE NEXT 25 YEARS (IN MILLIONS)
FIGURE 2 PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050
FIGURE 3 WORLDWIDE PREVALENCE OF PRESBYOPIA 2015, 2020 & 2050 (BILLION)
FIGURE 4 PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL IN 2013, 2020 & 2040 (MILLION)
FIGURE 5 GLOBAL HEALTHCARE EXPENDITURE (% OF GDP) 2012-2014
FIGURE 6 HEALTHCARE EXPENDITURE OF DEVELOPED ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 7 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP IN 2016
FIGURE 8 GLOBAL OPHTHALMIC DRUGS MARKET IN PRESCRIPTION OPHTHALMIC DRUGS 2017-2025 ($ MILLION)
FIGURE 9 GLOBAL OPHTHALMIC DRUGS MARKET IN OTC 2017-2025 ($ MILLION)
FIGURE 10 GLOBAL OPHTHALMIC DRUGS MARKET IN HOSPITALS OPHTHALMIC DRUGS 2017-2025 ($ MILLION)
FIGURE 11 GLOBAL OPHTHALMIC DRUGS MARKET IN EYE CLINICS OPHTHALMIC DRUGS 2017-2025 ($ MILLION)
FIGURE 12 EYE DISEASES CASES IN MILLION ABOVE AGE OF 40 IN AMERICA 2015
FIGURE 13 GLOBAL OPHTHALMIC DRUGS MARKET IN DIAGNOSTIC CENTERS 2017-2025 ($ MILLION)
FIGURE 14 TOTAL VISUAL IMPAIRMENT AND BLINDNESS CASES ABOVE AGE 40 IN US IN 2015 (IN MILLION)
FIGURE 15 EYE INJURY CASES ABOVE 40 YEARS IN AMERICA 2014 (MILLION)
FIGURE 16 GLOBAL OPHTHALMIC DRUGS MARKET IN PATIENTS OPHTHALMIC DRUGS 2017 - 2025 ($ MILLION)
FIGURE 17 GLOBAL OPHTHALMIC DRUGS MARKET IN DIABETIC MACULAR EDEMA 2017-2025 ($ MILLION)
FIGURE 18 GLOBAL OPHTHALMIC DRUGS MARKET IN EYE CANCER 2017-2025 ($ MILLION)
FIGURE 19 DIABETIC RETINOPATHY PREVALENCE IN THE U.S. 2011 & 2030 (MILLION)
FIGURE 20 GLOBAL OPHTHALMIC DRUGS MARKET IN DIABETIC RETINOPATHY 2017-2025 ($ MILLION)
FIGURE 21 GLOBAL OPHTHALMIC DRUGS MARKET IN RETINAL VEIN OCCLUSION 2017-2025 ($ MILLION)
FIGURE 22 GLOBAL OPHTHALMIC DRUGS MARKET IN AGE-RELATED MACULAR DEGENERATION 2017-2025 ($ MILLION)
FIGURE 23 GLOBAL OPHTHALMIC DRUGS MARKET IN CONJUNCTIVITIS 2017-2025 ($ MILLION)
FIGURE 24 GLOBAL OPHTHALMIC DRUGS MARKET IN DRY EYE 2017-2025 ($ MILLION)
FIGURE 25 GLOBAL OPHTHALMIC DRUGS MARKET IN GLAUCOMA THERAPEUTICS 2017-2025 ($ MILLION)
FIGURE 26 GLOBAL OPHTHALMIC DRUGS MARKET IN KERATITIS 2017-2025 ($ MILLION)
FIGURE 27 GLOBAL OPHTHALMIC DRUGS MARKET IN GEOGRAPHIC ATROPHY 2017-2025 ($ MILLION)
FIGURE 28 NORTH AMERICA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 29 U.S. POPULATION AGES 65 AND OLDER, 1960 TO 2060 (MILLION)
FIGURE 30 US OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 31 CAUSES OF VISUAL IMPAIRMENT IN US, 2014
FIGURE 32 CANADA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 33 PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2014
FIGURE 34 FINANCIAL COST SHARE OF RETINA DISORDER TREATMENT IN CANADA
FIGURE 35 MEXICO OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 36 PERCENTAGE OF PEOPLE AGED 65+, MEXICO (1950-2050)
FIGURE 37 PROPORTION OF DIRECT COST OF EYE DISEASE IN MEXICO, BY PAYER
FIGURE 38 EUROPE OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 39 DEVELOPMENT OF THE EUROPEAN POPULATION AGED 65 AND OVER, 2010, 2025 & 2050 (IN MILLION)
FIGURE 40 PROPORTION OF OPTOMETRISTS AND OPTICIANS IN EUROPEAN COUNTRIES 2015
FIGURE 41 GERMANY OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 42 POPULATION AGES 65 AND ABOVE (% OF TOTAL)
FIGURE 43 NUMBER OF LASIK SURGERIES IN GERMANY 2012-2014 (1000S)
FIGURE 44 UK OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 45 PROJECTED NUMBER OF PEOPLE LIVING WITH SIGHT LOSS IN THE UK (IN MILLION)
FIGURE 46 RUSSIA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 47 POPULATION AGES 65 AND ABOVE IN FRANCE (% OF TOTAL)
FIGURE 48 FRANCE OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 49 POPULATION AGES 65 AND ABOVE IN ITALY (% OF TOTAL)
FIGURE 50 ITALY OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 51 POPULATION AGES 65 AND ABOVE IN SPAIN (% OF TOTAL)
FIGURE 52 SPAIN OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 53 ASIA PACIFIC OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 54 CHINA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 55 INDIA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 56 SOUTH KOREA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 57 NUMBER OF YEARS FOR PERCENTAGE AGED 65 AND ABOVE IN TOTAL POPULATION TO TRIPLE
FIGURE 58 POPULATION AGES 65 AND ABOVE IN JAPAN (% OF TOTAL)
FIGURE 59 JAPAN OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 60 POPULATION AGES 65 AND ABOVE IN AUSTRALIA (% OF TOTAL)
FIGURE 61 AUSTRALIA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 62 MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 63 PATIENTS VISITS DUBAI HEALTHCARE CITY 2014-2015 (IN MILLION)
FIGURE 64 CENTRAL & SOUTH AMERICA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 65 AGING POPULATION GROWTH RATE, 2000-2050
FIGURE 66 AGING POPULATION IN COLOMBIA 1950-2050 (IN THOUSANDS)
FIGURE 67 GLOBAL OPHTHALMIC DRUG MARKET SHARE 2016(%)
COMPANIES MENTIONED
1. ABBOTT LABORATORIES
2. ALLERGAN INC.
3. JOHNSON AND JOHNSON
4. BAYER
5. VALEANT
6. REGENERON
7. AKORN
8. EYEMED
9. SENJU PHARMACEUTICAL CO., LTD
10. PFIZER INC.
11. MERCK & CO.
12. NOVARTIS AG
13. GLAXOSMITHKLINE
14. EYEGATE PHARMACEUTICALS
15. LPATH INCORPORATED
16. ROCHE HOLDING AG
17. SANTEN PHARMACEUTICAL CO. LTD
18. CIPLA PHARMACEUTICALS
19. SUN PHARMACEUTICALS INDUSTRIES, LTD.
FIGURE 1 THE POPULATION OF PEOPLE AGED 65 AND OVER WILL DOUBLE IN THE NEXT 25 YEARS (IN MILLIONS)
FIGURE 2 PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050
FIGURE 3 WORLDWIDE PREVALENCE OF PRESBYOPIA 2015, 2020 & 2050 (BILLION)
FIGURE 4 PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL IN 2013, 2020 & 2040 (MILLION)
FIGURE 5 GLOBAL HEALTHCARE EXPENDITURE (% OF GDP) 2012-2014
FIGURE 6 HEALTHCARE EXPENDITURE OF DEVELOPED ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 7 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP IN 2016
FIGURE 8 GLOBAL OPHTHALMIC DRUGS MARKET IN PRESCRIPTION OPHTHALMIC DRUGS 2017-2025 ($ MILLION)
FIGURE 9 GLOBAL OPHTHALMIC DRUGS MARKET IN OTC 2017-2025 ($ MILLION)
FIGURE 10 GLOBAL OPHTHALMIC DRUGS MARKET IN HOSPITALS OPHTHALMIC DRUGS 2017-2025 ($ MILLION)
FIGURE 11 GLOBAL OPHTHALMIC DRUGS MARKET IN EYE CLINICS OPHTHALMIC DRUGS 2017-2025 ($ MILLION)
FIGURE 12 EYE DISEASES CASES IN MILLION ABOVE AGE OF 40 IN AMERICA 2015
FIGURE 13 GLOBAL OPHTHALMIC DRUGS MARKET IN DIAGNOSTIC CENTERS 2017-2025 ($ MILLION)
FIGURE 14 TOTAL VISUAL IMPAIRMENT AND BLINDNESS CASES ABOVE AGE 40 IN US IN 2015 (IN MILLION)
FIGURE 15 EYE INJURY CASES ABOVE 40 YEARS IN AMERICA 2014 (MILLION)
FIGURE 16 GLOBAL OPHTHALMIC DRUGS MARKET IN PATIENTS OPHTHALMIC DRUGS 2017 - 2025 ($ MILLION)
FIGURE 17 GLOBAL OPHTHALMIC DRUGS MARKET IN DIABETIC MACULAR EDEMA 2017-2025 ($ MILLION)
FIGURE 18 GLOBAL OPHTHALMIC DRUGS MARKET IN EYE CANCER 2017-2025 ($ MILLION)
FIGURE 19 DIABETIC RETINOPATHY PREVALENCE IN THE U.S. 2011 & 2030 (MILLION)
FIGURE 20 GLOBAL OPHTHALMIC DRUGS MARKET IN DIABETIC RETINOPATHY 2017-2025 ($ MILLION)
FIGURE 21 GLOBAL OPHTHALMIC DRUGS MARKET IN RETINAL VEIN OCCLUSION 2017-2025 ($ MILLION)
FIGURE 22 GLOBAL OPHTHALMIC DRUGS MARKET IN AGE-RELATED MACULAR DEGENERATION 2017-2025 ($ MILLION)
FIGURE 23 GLOBAL OPHTHALMIC DRUGS MARKET IN CONJUNCTIVITIS 2017-2025 ($ MILLION)
FIGURE 24 GLOBAL OPHTHALMIC DRUGS MARKET IN DRY EYE 2017-2025 ($ MILLION)
FIGURE 25 GLOBAL OPHTHALMIC DRUGS MARKET IN GLAUCOMA THERAPEUTICS 2017-2025 ($ MILLION)
FIGURE 26 GLOBAL OPHTHALMIC DRUGS MARKET IN KERATITIS 2017-2025 ($ MILLION)
FIGURE 27 GLOBAL OPHTHALMIC DRUGS MARKET IN GEOGRAPHIC ATROPHY 2017-2025 ($ MILLION)
FIGURE 28 NORTH AMERICA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 29 U.S. POPULATION AGES 65 AND OLDER, 1960 TO 2060 (MILLION)
FIGURE 30 US OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 31 CAUSES OF VISUAL IMPAIRMENT IN US, 2014
FIGURE 32 CANADA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 33 PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2014
FIGURE 34 FINANCIAL COST SHARE OF RETINA DISORDER TREATMENT IN CANADA
FIGURE 35 MEXICO OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 36 PERCENTAGE OF PEOPLE AGED 65+, MEXICO (1950-2050)
FIGURE 37 PROPORTION OF DIRECT COST OF EYE DISEASE IN MEXICO, BY PAYER
FIGURE 38 EUROPE OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 39 DEVELOPMENT OF THE EUROPEAN POPULATION AGED 65 AND OVER, 2010, 2025 & 2050 (IN MILLION)
FIGURE 40 PROPORTION OF OPTOMETRISTS AND OPTICIANS IN EUROPEAN COUNTRIES 2015
FIGURE 41 GERMANY OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 42 POPULATION AGES 65 AND ABOVE (% OF TOTAL)
FIGURE 43 NUMBER OF LASIK SURGERIES IN GERMANY 2012-2014 (1000S)
FIGURE 44 UK OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 45 PROJECTED NUMBER OF PEOPLE LIVING WITH SIGHT LOSS IN THE UK (IN MILLION)
FIGURE 46 RUSSIA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 47 POPULATION AGES 65 AND ABOVE IN FRANCE (% OF TOTAL)
FIGURE 48 FRANCE OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 49 POPULATION AGES 65 AND ABOVE IN ITALY (% OF TOTAL)
FIGURE 50 ITALY OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 51 POPULATION AGES 65 AND ABOVE IN SPAIN (% OF TOTAL)
FIGURE 52 SPAIN OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 53 ASIA PACIFIC OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 54 CHINA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 55 INDIA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 56 SOUTH KOREA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 57 NUMBER OF YEARS FOR PERCENTAGE AGED 65 AND ABOVE IN TOTAL POPULATION TO TRIPLE
FIGURE 58 POPULATION AGES 65 AND ABOVE IN JAPAN (% OF TOTAL)
FIGURE 59 JAPAN OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 60 POPULATION AGES 65 AND ABOVE IN AUSTRALIA (% OF TOTAL)
FIGURE 61 AUSTRALIA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 62 MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 63 PATIENTS VISITS DUBAI HEALTHCARE CITY 2014-2015 (IN MILLION)
FIGURE 64 CENTRAL & SOUTH AMERICA OPHTHALMIC DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 65 AGING POPULATION GROWTH RATE, 2000-2050
FIGURE 66 AGING POPULATION IN COLOMBIA 1950-2050 (IN THOUSANDS)
FIGURE 67 GLOBAL OPHTHALMIC DRUG MARKET SHARE 2016(%)
COMPANIES MENTIONED
1. ABBOTT LABORATORIES
2. ALLERGAN INC.
3. JOHNSON AND JOHNSON
4. BAYER
5. VALEANT
6. REGENERON
7. AKORN
8. EYEMED
9. SENJU PHARMACEUTICAL CO., LTD
10. PFIZER INC.
11. MERCK & CO.
12. NOVARTIS AG
13. GLAXOSMITHKLINE
14. EYEGATE PHARMACEUTICALS
15. LPATH INCORPORATED
16. ROCHE HOLDING AG
17. SANTEN PHARMACEUTICAL CO. LTD
18. CIPLA PHARMACEUTICALS
19. SUN PHARMACEUTICALS INDUSTRIES, LTD.
